AI isn’t just speeding up biotech—it’s rewriting the rules. In this panel, experts from Moderna and Pfizer share how generative models are enabling faster target identification, smarter trial design, and next-gen personalized therapies.
We’ll explore the real-world impact of AI on pipelines, platforms, systems and patient outcomes—and how the most advanced biotechs are building for the future.
With over two decades of experience leading the development and deployment of digital solutions in the pharmaceutical industry, I have spearheaded data science initiatives that optimize every stage of the clinical trial lifecycle. My expertise includes leading teams to harness machine learning for improved patient recruitment, integrating novel digital endpoints for deeper insights into drug efficacy, employing ML techniques for risk-based data monitoring, and automating regulatory document authoring using generative AI.
At Biogen and through my consultancy, I have integrated digital technologies into clinical trials to streamline processes and enhance outcomes. At Harvard and MIT, I developed open-source Python tools for digital health and fostered industry-academia collaborations. I have published over 60 high-impact papers with over 2,000 citations and hold two patents in digital health technologies. Adept at leading cross-functional teams, I seamlessly merge technology and healthcare to accelerate clinical trials and drive strategic objectives.